217 related articles for article (PubMed ID: 27418969)
21. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Tesic D; Kostic M; Paunovic D; Jankovic SM
Kardiol Pol; 2015; 73(4):287-95. PubMed ID: 25428811
[TBL] [Abstract][Full Text] [Related]
22. Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Adlan AM; Lip GY
Drug Saf; 2013 Feb; 36(2):93-110. PubMed ID: 23329540
[TBL] [Abstract][Full Text] [Related]
23. Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Holmes AP; Saxena P; Kabir SN; O'Shea C; Kuhlmann SM; Gupta S; Fobian D; Apicella C; O'Reilly M; Syeda F; Reyat JS; Smith GL; Workman AJ; Pavlovic D; Fabritz L; Kirchhof P
Heart Rhythm; 2021 Jul; 18(7):1212-1220. PubMed ID: 33737232
[TBL] [Abstract][Full Text] [Related]
24. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
[TBL] [Abstract][Full Text] [Related]
25. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
Khachatryan A; Merino JL; de Abajo FJ; Botto GL; Kirchhof P; Breithardt G; Stambler B; Abenhaim L; Grimaldi-Bensouda L
Europace; 2022 Jul; 24(6):899-909. PubMed ID: 34792111
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Wu VC; Wang CL; Huang YC; Tu HT; Huang YT; Huang CH; Chen SW; Kuo CF; Hung KC; Chang SH
Europace; 2023 May; 25(5):. PubMed ID: 37000581
[TBL] [Abstract][Full Text] [Related]
27. Amiodarone and dronedarone: An update.
Vamos M; Hohnloser SH
Trends Cardiovasc Med; 2016 Oct; 26(7):597-602. PubMed ID: 27155812
[TBL] [Abstract][Full Text] [Related]
28. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
D'Angelo RN; Rahman M; Khanna R; Yeh RW; Goldstein L; Yadalam S; Kalsekar I; Tung P; Zimetbaum PJ
J Cardiovasc Electrophysiol; 2021 Jun; 32(6):1529-1537. PubMed ID: 33760297
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation].
Sánchez Soriano RM; Chamorro Fernández CI; Ruiz Nodar JM; Chamorro Fernández AJ; Grau Jornet G; Nuñez Villota J
Arch Cardiol Mex; 2018; 88(3):204-211. PubMed ID: 28864237
[TBL] [Abstract][Full Text] [Related]
30. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Joseph AP; Ward MR
Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
[TBL] [Abstract][Full Text] [Related]
31. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C; Valembois L; Bergmann JF; Belmin J
Cochrane Database Syst Rev; 2015 Mar; (3):CD005049. PubMed ID: 25820938
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
Gao S; Juhaeri J; Schiappacasse HA; Koren AT; Dai WS
Clin Ther; 2011 Oct; 33(10):1483-1490.e3. PubMed ID: 21959260
[TBL] [Abstract][Full Text] [Related]
33. Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
Pamukcu B; Lip GY
Expert Opin Pharmacother; 2010 Dec; 11(17):2775-8. PubMed ID: 21050033
[TBL] [Abstract][Full Text] [Related]
34. Rhythm control agents and adverse events in patients with atrial fibrillation.
Taylor CJ; Hodgkinson J; Hobbs FD
Int J Clin Pract; 2010 Jul; 64(8):1069-75. PubMed ID: 20487051
[TBL] [Abstract][Full Text] [Related]
35. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Wolbrette D; Gonzalez M; Samii S; Banchs J; Penny-Peterson E; Naccarelli G
Vasc Health Risk Manag; 2010 Aug; 6():517-23. PubMed ID: 20730068
[TBL] [Abstract][Full Text] [Related]
36. Atrial fibrillation: rate control often better than rhythm control.
Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Khan MH; Rochlani Y; Aronow WS
Expert Opin Drug Saf; 2017 Dec; 16(12):1407-1412. PubMed ID: 28960089
[TBL] [Abstract][Full Text] [Related]
38. Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations.
Singh BN
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):31S-5S. PubMed ID: 21098417
[TBL] [Abstract][Full Text] [Related]
39. Dronedarone.
Tamargo J; López-Farré A; Caballero R; Delpón E
Drugs Today (Barc); 2011 Feb; 47(2):109-33. PubMed ID: 21431100
[TBL] [Abstract][Full Text] [Related]
40. Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.
Prystowsky EN
Nat Rev Cardiol; 2010 Jan; 7(1):5-6. PubMed ID: 20019753
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
